Targeting cancer stem cell pathways for cancer therapy (DOI: 10.1038/s41392-020-0110-5)

From Wikibase.slis.ua.edu
Jump to navigation Jump to search


Publication Metadata
KeywordsCancer stem cells
DOI10.1038/s41392-020-0110-5
PubMedID32047658
PMCIDPMC7005297
Sections in this Publication
SectionSection 1: Introduction (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5)
SectionSection 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5)
Author(s) [max 10]
1stLiqun Yang (1st author of 10.1038/s41392-020-0110-5)
2ndPengfei Shi (2nd author of 10.1038/s41392-020-0110-5)
3rdGaichao Zhao (3rd author of 10.1038/s41392-020-0110-5)
4thJie Xu (4th author of 10.1038/s41392-020-0110-5)
5thXiaowen Wang (8th author of 10.1038/s41392-020-0110-5)
6thJiayi Zhang (6th author of 10.1038/s41392-020-0110-5)
7thGuanghui Zhang (7th author of 10.1038/s41392-020-0110-5)
9thZhen Dong (9th author of 10.1038/s41392-020-0110-5)
10thFei Chen (10th author of 10.1038/s41392-020-0110-5)
DatasetCOVID-19 Open Research Dataset (CORD-19). 2020. Version 2020-03-20.

Research article published as:
Signal Transduct Target Ther; 2020 ; 5 8 http://doi.org/10.1038/s41392-020-0110-5

Abstract

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been considered promising therapeutic targets for cancer therapy. These cells have self-renewal capacity and differentiation potential and contribute to multiple tumor malignancies, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance. The biological activities of CSCs are regulated by several pluripotent transcription factors, such as OCT4, Sox2, Nanog, KLF4, and MYC. In addition, many intracellular signaling pathways, such as Wnt, NF-kappaB (nuclear factor-kappaB), Notch, Hedgehog, JAK-STAT (Janus kinase/signal transducers and activators of transcription), PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mammalian target of rapamycin), TGF (transforming growth factor)/SMAD, and PPAR (peroxisome proliferator-activated receptor), as well as extracellular factors, such as vascular niches, hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, cancer-associated mesenchymal stem cells, extracellular matrix, and exosomes, have been shown to be very important regulators of CSCs. Molecules, vaccines, antibodies, and CAR-T (chimeric antigen receptor T cell) cells have been developed to specifically target CSCs, and some of these factors are already undergoing clinical trials. This review summarizes the characterization and identification of CSCs, depicts major factors and pathways that regulate CSC development, and discusses potential targeted therapy for CSCs.

License

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.